Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Rectal Neoplasms 1Neoplasm Metastasis 1Liver Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

Sorafenib 3atezolizumab 2Radiotherapy 2Bevacizumab 2tremelimumab 1temsirolimus 1lonafarnib 1liposomal doxorubicin 1infigratinib 1gadolinium ethoxybenzyl DTPA 1fludarabine 1durvalumab 1cabozantinib 1bavituximab 1aldesleukin 1Thoracoscopy 1Thoracic Surgery, Video-Assisted 1Resveratrol 1Radiosurgery 1Radionuclide Generators 1Radiofrequency Ablation 1Polymerase Chain Reaction 1Oxaliplatin 1Nivolumab 1NSC 366140 1Mass Spectrometry 1Immunotherapy 1Immunohistochemistry 1Genetic Testing 1Gemcitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Liver Neoplasms × lonafarnib × Clear all
NCT00020774 2020-07-31

SCH 66336 With or Without Gemcitabine Followed by Surgery Compared With Surgery Alone in Treating Patients With Primary Liver Cancer

Jonsson Comprehensive Cancer Center

Phase 2 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡